Rani Therapeutics Holdings

Rani Therapeutics Holdings

RANI· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -1.5% in FY2025

Talat Imran is the CEO of Rani Therapeutics Holdings and was paid $1.1M in FY2025 (Dec).

Pay$100 in the stock at the end of FY21 → $20
CEO pay is from each Rani Therapeutics Holdings proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Talat ImranFY2025
  2. 2Svai SanfordFY2025
  3. 3Kate McKinleyFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Rani Therapeutics Holdings paid its 3 named executives $2.9M in total in FY2025 (Dec). CEO Talat Imran was paid $1.1M of that.

Name
Talat ImranChief Executive OfficerNot disclosed
Svai SanfordChief Financial Officer
Kate McKinleyChief Business OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Rani Therapeutics Holdings. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board2

See all
  • Dennis AusielloDirector · 7 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance—Paid as an executive
  • Vasudev BaileyDirector · 0 yr on the boardIndependentCompensation (Chair)—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 16, 2026FY2025
Annual report10-KMar 26, 2026FY2025
Proxy statementDEF 14AApr 16, 2025FY2024
Annual report10-KMar 31, 2025FY2024
Proxy statementDEF 14AApr 17, 2024FY2023
Annual report10-KMar 20, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data